^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Hodgkin Lymphoma
    Regimen: (cyclophosphamide + doxorubicin hydrochloride + prednisone + Rituxan (rituximab) + vincristine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/14/2020
    Excerpt:
    Hodgkin Lymphoma: NLPHL, second-line options added:…R-CHOP...